Assembly Biosciences (ASMB) Expected to Announce Earnings on Thursday

Assembly Biosciences (NASDAQ:ASMB) will likely be posting its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Assembly Biosciences to post earnings of ($0.51) per share and revenue of $7.42 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Assembly Biosciences Price Performance

ASMB opened at $28.53 on Wednesday. Assembly Biosciences has a 12 month low of $7.75 and a 12 month high of $39.71. The stock has a market cap of $451.34 million, a P/E ratio of -5.96 and a beta of 1.11. The stock’s 50 day moving average price is $28.39 and its 200 day moving average price is $29.58.

Analyst Ratings Changes

Several research firms have recently issued reports on ASMB. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, December 22nd. Finally, Mizuho set a $40.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research report on Thursday, November 20th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.75.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. acquired a new position in shares of Assembly Biosciences during the third quarter valued at $26,122,000. Janus Henderson Group PLC increased its position in Assembly Biosciences by 11.3% in the fourth quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock worth $28,540,000 after purchasing an additional 85,299 shares during the period. Paradigm Biocapital Advisors LP bought a new stake in Assembly Biosciences during the 4th quarter worth about $22,625,000. Vanguard Group Inc. lifted its position in Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares during the period. Finally, Parkman Healthcare Partners LLC acquired a new position in Assembly Biosciences during the 3rd quarter valued at about $6,425,000. 19.92% of the stock is owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.